{"id":"gardasil-merck-co-inc","safety":{"commonSideEffects":[{"rate":"~80%","effect":"Injection site pain"},{"rate":"~25%","effect":"Injection site swelling"},{"rate":"~25%","effect":"Injection site erythema"},{"rate":"~10%","effect":"Fever"},{"rate":"~10%","effect":"Headache"},{"rate":"~5%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gardasil contains virus-like particles (VLPs) derived from the major capsid protein of HPV types 6, 11, 16, and 18. These VLPs are non-infectious but immunogenic, triggering a humoral immune response that generates neutralizing antibodies. These antibodies prevent HPV infection of epithelial cells, thereby reducing the risk of HPV-related cancers and diseases.","oneSentence":"Gardasil is a recombinant vaccine that stimulates the immune system to produce antibodies against human papillomavirus (HPV) types to prevent infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:17.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of anal cancer and other HPV-related cancers"}]},"trialDetails":[{"nctId":"NCT04782895","phase":"PHASE3","title":"Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2021-03-14","conditions":"Cervical Cancer, Condylomata Acuminata","enrollment":488},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT00806676","phase":"NA","title":"Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2008-12","conditions":"Chronic Kidney Disease","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":97,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gardasil ® (Merck & Co. Inc)","genericName":"Gardasil ® (Merck & Co. Inc)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gardasil is a recombinant vaccine that stimulates the immune system to produce antibodies against human papillomavirus (HPV) types to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}